J. Dirk Iglehart
Papers
1
Total Citations
42
H-Index
1
About
J. Dirk Iglehart is a leading surgical oncologist whose research has fundamentally advanced the understanding and detection of breast cancer, particularly HER2-positive disease. His work bridges molecular biology and clinical practice, focusing on identifying novel biomarkers for early cancer detection and monitoring treatment response. In a landmark 2006 study, Iglehart and his team discovered that declining levels of a specific plasma fibrinogen alpha fragment could identify HER2-positive breast cancer patients—a finding with profound implications for non-invasive diagnostics. This work, cited over 40 times, demonstrated that blood-based biomarkers could potentially complement traditional radiological screening, offering a simpler, more accessible method for detecting aggressive breast cancer subtypes. Notably, his research showed that these biomarker levels reverted to normal after surgical removal of tumors, underscoring their specificity and potential for monitoring disease recurrence. Iglehart’s contributions have helped pave the way for liquid biopsy approaches in breast cancer management, making him a pivotal figure in the quest for personalized, minimally invasive cancer care.
Research Focus
Key Achievements
Top Papers
- 1